Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials

Pharmacogenomics J. 2009 Apr;9(2):111-5. doi: 10.1038/tpj.2008.10. Epub 2008 Sep 9.


Twin studies document substantial heritability for successful abstinence from smoking. A genome-wide association study has identified markers whose allele frequencies differ with nominal P<0.005 in nicotine-dependent clinical trial participants who were successful vs unsuccessful in abstaining from smoking; many of these results are also supported by data from two additional samples. More study is required to precisely determine the variance in quitting success that can be accounted for by the single-nucleotide polymorphisms that are currently identified and to precisely classify individuals who may display varying degrees of genetic vs environmental effects into quitters or nonquitters. However, the data at hand do allow us to model the effects of genotypic stratification in smoking cessation trials. We identify relationships between the costs of identifying and genotyping prospective trial participants vs the costs of performing the clinical trials. We quantitate the increasing savings that result from genetically stratified designs as recruiting/genotyping costs go down and trial costs increase. This model helps to define the circumstances in which genetically stratified designs may enhance power and reduce costs for smoking cessation clinical trials.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Clinical Trials as Topic* / economics
  • Computer Simulation
  • Cost Savings
  • Genetic Testing / economics
  • Genotype
  • Humans
  • Models, Economic
  • Models, Genetic
  • Patient Selection*
  • Phenotype
  • Smoking / genetics*
  • Smoking Cessation*
  • Smoking Prevention*
  • Tobacco Use Disorder / genetics*
  • Tobacco Use Disorder / therapy*
  • Treatment Outcome